Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Charité Should Be Paid At Same Rate As Spinal Fusion – J&J/DePuy

This article was originally published in The Gray Sheet

Executive Summary

The procedure code for J&J/DePuy Charité artificial disc should be mapped to the same DRGs as spinal fusion to ensure adequate reimbursement for fiscal year 2005, according to the firm

You may also be interested in...



FY 2005 Medicare Inpatient Payment Rule In Brief

Implantable defibrillator payments: CMS appears to be waiting to determine ICD payments until it issues a decision expanding national coverage based on the SCD-HeFT trial population, expected by year-end. The agency came under heavy fire from industry and professional societies for soliciting comments in the inpatient prospective payment system proposed rule on ways to encourage less expensive use of ICDs when clinically appropriate (1"The Gray Sheet" July 5, 2004, p. 8). The final rule does not discuss stakeholder comments or a final policy...

FY 2005 Medicare Inpatient Payment Rule In Brief

Implantable defibrillator payments: CMS appears to be waiting to determine ICD payments until it issues a decision expanding national coverage based on the SCD-HeFT trial population, expected by year-end. The agency came under heavy fire from industry and professional societies for soliciting comments in the inpatient prospective payment system proposed rule on ways to encourage less expensive use of ICDs when clinically appropriate (1"The Gray Sheet" July 5, 2004, p. 8). The final rule does not discuss stakeholder comments or a final policy...

J&J/DePuy Charité Artificial Spinal Disc Unanimously Backed By FDA Panel

Johnson & Johnson/DePuy Spine should collect two years of postmarket follow-up data on Charité artificial lumbar disc recipients, according to FDA's Orthopaedic & Rehabilitation Devices Panel

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel